Cell therapy represents one of the most transformative applications of synthetic biology in medicine. By engineering living cells to perform therapeutic functions, cell therapies can achieve outcomes impossible with traditional small molecule or biologic drugs. The cells can sense disease-associated signals, migrate to affected tissues, persist and proliferate in the patient, and adapt their response over time. This programmable, living drug paradigm has already demonstrated curative potential in certain cancers and is being extended to autoimmune diseases, solid tumors, and regenerative medicine.
The cell therapy industry has grown rapidly since the approval of the first CAR-T therapies in 2017. ArsenalBio is applying synthetic biology and CRISPR engineering to build next-generation T cell therapies with integrated genetic circuits that enhance persistence and anti-tumor activity. Obsidian Therapeutics developed regulatable gene expression systems for cell therapies, while Fate Therapeutics engineers iPSC-derived cell products that can be manufactured at scale as off-the-shelf therapies. Companies like Tmunity (now part of Roche) and Lyell Immunopharma are engineering T cell fitness to overcome the immunosuppressive tumor microenvironment that limits current cell therapies.
Manufacturing remains a critical challenge for cell therapy. Traditional autologous approaches, where each patient's cells are individually harvested, engineered, and expanded, create complex logistics and high costs exceeding $300,000 per treatment. Allogeneic (universal donor) approaches using CRISPR-edited cells from healthy donors promise to reduce costs and improve access. Companies like CRISPR Therapeutics and Caribou Biosciences are developing allogeneic cell therapies with edited immune evasion genes, aiming to create off-the-shelf products that can be manufactured in advance and administered to any patient without immune rejection.